Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06337643 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Tolerability, Safety and Immunogenicity of MVX01 Pneumococcal Vaccine
A Phase 1 study of Pneumococcal Vaccine, sponsored by Matrivax Research and Development Corporation.
- Active
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
- 2
- Study locations
NCT06337643: Active Phase 1 study of Pneumococcal Vaccine, sponsored by Matrivax Research and Development Corporation.
NCT06337643 is a Phase 1 study of Pneumococcal Vaccine that is active but no longer recruiting, run by Matrivax Research and Development Corporation. The registered enrollment target is 75 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (25% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06337643, a Phase 1 study of Pneumococcal Vaccine, is active but no longer recruiting, sponsored by Matrivax Research and Development Corporation.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
- 2
- Study locations
Study Summary
The objectives of this first-in-human study is to evaluate the tolerability, safety, and immunogenicity of MVX01, a pneumococcal vaccine candidate, at four dose levels.
Conditions Studied
Interventions
- BIOLOGICAL MVX01
- BIOLOGICAL MVX01 Placebo
Study Locations (2)
Georgia
- Velocity (Meridian) Clinical Research - Savannah
Tennessee
- Alliance for Multispecialty Research (AMR) - Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2023-03-07 |
| Est. Completion | 2024-04-16 |
| Phase | Phase 1 |
What the registry record for NCT06337643 still lists
NCT06337643 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (25% higher).
The record links to 1 condition, with Pneumococcal Vaccine appearing as the primary indexed condition, and to 2 interventions - of which MVX01 is the first listed.
NCT06337643 reports a single indexed study location in Georgia, Tennessee.
Frequently Asked Questions
What is clinical trial NCT06337643 about?
NCT06337643 is a clinical study titled "A Study to Evaluate Tolerability, Safety and Immunogenicity of MVX01 Pneumococcal Vaccine". The objectives of this first-in-human study is to evaluate the tolerability, safety, and immunogenicity of MVX01, a pneumococcal vaccine candidate, at four dose levels.
What is the current status of trial NCT06337643?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2023-03-07. Estimated completion is 2024-04-16.
What conditions does trial NCT06337643 study?
This clinical trial studies the following conditions: Pneumococcal Vaccine.
What interventions are being tested in trial NCT06337643?
The interventions under investigation include: MVX01 (BIOLOGICAL), MVX01 Placebo (BIOLOGICAL).
Who is sponsoring clinical trial NCT06337643?
This trial is sponsored by Matrivax Research and Development Corporation, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06337643 being conducted?
This trial has 2 study locations across Georgia, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pneumococcal Vaccine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06337643's enrollment target sits among peer trials
75 711th of 2000 higher than 1,276 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI